dbo:abstract |
Daprodustat (INN, trade name Duvroq in Japan, development code GSK1278863) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Daprodustat was approved in Japan in June 2020 for the treatment of patients with anemia due to chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs. In October 2022, US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) recommended daprodustat for adult dialysis patients with anaemia of chronic kidney disease (CKD). The advisory committee experts, however, voted against the use of daprodustat in non-dialysis patients with anaemia of CKD, citing increased safety risks such as heart failure and bleeding gastric erosions. (en) ダプロデュスタット(Daprodustat(INN)、GSK1278863)は、低酸素誘導因子プロリン水酸化酵素阻害薬(HIF-PH阻害剤、hypoxia-inducible factor prolyl-hydroxylase inhibitor、HIF-PHI)として作用する薬剤で、それによって内因性エリスロポエチンの産生刺激、ヘモグロビンおよび赤血球の産生を増加させる。慢性腎臓病に続発する貧血()の治療を目的とし、グラクソ・スミスクラインより「ダーブロック錠」として2020年8月26日に発売された。 アスレチックドーピングへの応用の可能性があるため、パフォーマンス向上薬のスクリーニングにも組み込まれている。 (ja) |
dbo:casNumber |
960539-70-2 |
dbo:chEMBL |
3544988 |
dbo:drugbank |
DB11682 |
dbo:fdaUniiCode |
JVR38ZM64B |
dbo:kegg |
D10874 |
dbo:pubchem |
91617630 |
dbo:thumbnail |
wiki-commons:Special:FilePath/Daprodustat_structure.png?width=300 |
dbo:wikiPageID |
55981442 (xsd:integer) |
dbo:wikiPageLength |
5359 (xsd:nonNegativeInteger) |
dbo:wikiPageRevisionID |
1119218559 (xsd:integer) |
dbo:wikiPageWikiLink |
dbr:Desidustat dbc:Acetic_acids dbc:Cyclohexyl_compounds dbr:Anemia dbr:Performance-enhancing_drugs dbr:HIF_prolyl-hydroxylase_inhibitor dbc:Pyrimidinediones dbr:Erythropoietin dbr:Food_and_Drug_Administration dbr:Chronic_kidney_disease dbr:Red_blood_cell dbr:Hemoglobin dbr:Roxadustat dbr:Molidustat dbr:Vadadustat dbr:Athletic_doping |
dbp:atcPrefix |
B03 (en) |
dbp:atcSuffix |
XA07 (en) |
dbp:c |
19 (xsd:integer) |
dbp:casNumber |
960539 (xsd:integer) |
dbp:chembl |
3544988 (xsd:integer) |
dbp:chemspiderid |
33427356 (xsd:integer) |
dbp:drugbank |
DB11682 (en) |
dbp:h |
27 (xsd:integer) |
dbp:iupacName |
2 (xsd:integer) |
dbp:kegg |
D10874 (en) |
dbp:legalStatus |
Rx-only (en) |
dbp:n |
3 (xsd:integer) |
dbp:o |
6 (xsd:integer) |
dbp:pubchem |
91617630 (xsd:integer) |
dbp:smiles |
C3CCCCC3ncnC2CCCCC2 (en) |
dbp:stdinchi |
1 (xsd:integer) |
dbp:stdinchikey |
NVTKJBXOBFRPLQ-UHFFFAOYSA-N (en) |
dbp:synonyms |
GSK1278863 (en) |
dbp:unii |
JVR38ZM64B (en) |
dbp:width |
250 (xsd:integer) |
dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Abbrlink dbt:Fdacite dbt:Blood-drug-stub |
dct:subject |
dbc:Acetic_acids dbc:Cyclohexyl_compounds dbc:Pyrimidinediones |
rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
rdfs:comment |
ダプロデュスタット(Daprodustat(INN)、GSK1278863)は、低酸素誘導因子プロリン水酸化酵素阻害薬(HIF-PH阻害剤、hypoxia-inducible factor prolyl-hydroxylase inhibitor、HIF-PHI)として作用する薬剤で、それによって内因性エリスロポエチンの産生刺激、ヘモグロビンおよび赤血球の産生を増加させる。慢性腎臓病に続発する貧血()の治療を目的とし、グラクソ・スミスクラインより「ダーブロック錠」として2020年8月26日に発売された。 アスレチックドーピングへの応用の可能性があるため、パフォーマンス向上薬のスクリーニングにも組み込まれている。 (ja) Daprodustat (INN, trade name Duvroq in Japan, development code GSK1278863) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Daprodustat was approved in Japan in June 2020 for the treatment of patients with anemia due to chronic kidney disease. (en) |
rdfs:label |
Daprodustat (en) ダプロデュスタット (ja) |
owl:sameAs |
wikidata:Daprodustat dbpedia-ja:Daprodustat https://global.dbpedia.org/id/2Y19t |
prov:wasDerivedFrom |
wikipedia-en:Daprodustat?oldid=1119218559&ns=0 |
foaf:depiction |
wiki-commons:Special:FilePath/Daprodustat_structure.png |
foaf:isPrimaryTopicOf |
wikipedia-en:Daprodustat |
is dbo:wikiPageRedirects of |
dbr:C19H27N3O6 |
is dbo:wikiPageWikiLink of |
dbr:Hypoxia-inducible_factor dbr:C19H27N3O6 dbr:HIF_prolyl-hydroxylase_inhibitor dbr:ATC_code_B03 dbr:Molidustat dbr:Vadadustat |
is foaf:primaryTopic of |
wikipedia-en:Daprodustat |